ACE inhibitor therapy: Possible effective prevention of new-onset atrial fibrillation following cardiac surgery by Dąbrowski, Rafał et al.
ORIGINAL ARTICLE
Cardiology Journal
2007, Vol. 14, No. 3, pp. 274280
Copyright ' 2007 Via Medica
ISSN 18975593
274 www.cardiologyjournal.org
Address for correspondence: Rafa‡ D„browski, MD, PhD
National Institute of Cardiology
2nd Department of Ischemic Heart Disease
Spartaæska 1, 02637 Warsaw, Poland
Tel./fax: +48 22 844 95 10; e-mail: rafal.dabrowski@epf.pl
Received: 8.01.2007 Accepted: 3.04.2007
ACE inhibitor therapy: Possible effective
prevention of new-onset atrial fibrillation
following cardiac surgery
Rafa‡ D„browski1, Cezary Sosnowski2, Agnieszka Jankowska1,
Grzegorz Religa1, Ilona Kowalik1 and Hanna Szwed1
12nd Department of Ischemic Heart Disease, Institute of Cardiology, Warsaw, Poland
21st Department of Ischemic Heart Disease, Institute of Cardiology, Warsaw, Poland
32nd Department of Cardiac Surgery, Institute of Cardiology, Warsaw, Poland
Abstract
Background: Atrial fibrillation (AF) is a common complication after coronary artery bypass
grafting (CABG). The aims of the study were to assess possible predictors and identify modes
of prevention of new-onset AF following coronary surgery.
Methods: Retrospective clinical and statistical analysis was made of the medical records of
217 patients who had undergone coronary surgery.
Results: AF occurred in 28% (61/217) of the patients. In univariate analysis the age of the
patients with AF was higher (p = 0.0033), they had a longer history of coronary disease (p = 0.0417)
and more had > 3 grafts (p < 0.05). Low ejection fraction (< 40%) was also a risk factor of
arrhythmia (p < 0.0001). In multivariate regression analysis two independent predictors of
AF were identified: no ACE inhibitor treatment before surgery (p = 0.0005) and age > 60 years
(p < 0.01). Patients with AF had a higher mean heart rate after the procedure: 115 – 34 vs.
78 – 21/min (p < 0.0005). Patients treated with ACE inhibitors before and after surgery had
a lower incidence of AF than non-treated patients: 8% vs. 48% (p < 0.0001) and 4% vs. 61%,
p < 0.0001) respectively. Beta-blocker treatment before and after surgery resulted in a lower
incidence of AF: at 23% vs. 75% (p < 0.001) and 19% vs. 96% (p < 0.0001), respectively.
Conclusions: No ACE inhibitor therapy before surgery, advanced age, low ejection fraction,
high post-procedure heart rate, duration of coronary disease and the number of grafts (corre-
sponding to the length of the procedure) were found to be strong probable predictors of AF
following cardiac surgery. ACE inhibitor therapy may be effective in the prevention of new-
onset AF. Treatment based on individual variables is crucial for proper treatment and to
diminish the risk of arrhythmia. (Cardiol J 2007; 14: 274280)
Key words: atrial fibrillation, cardiovascular surgery, beta-blockers, angiotensin-
-converting enzyme inhibitors
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Introduction
Atrial fibrillation (AF) is a common complica-
tion after coronary artery bypass grafting (CABG).
On the basis of a summary of 40 randomised (2270
patients) and 6 observational (16050 patients) tri-
als this arrhythmia occurs in approximately 550%
of patients [1, 2]. The consequences of AF are seri-
ous. Besides longer hospitalisation, there is a high-
er risk of cerebrovascular incidents, exacerbation
of congestive heart failure, renal complications and
a need for pacemaker implantation, all increasing
the costs of treatment [2]. Arrhythmia is very com-
mon during the first three to five days of intensive
care and is commonly treated with beta-blockers
and other anti-arrhythmic drugs such as amiodar-
one, propafenone or verapamil. The precipitating
causes of AF are considered to be indirect: volume
expansion leading to acute atrial stretch, atrial and/or
ventricular ischemia, sympathetic activation that
alters atrial refractoriness and increases automatism
and metabolic and electrolyte abnormalities [3].
Advanced age, low ejection fraction, male gender,
duration of surgery and hypertension are factors
that have been proven to increase the risk of AF.
There is no significant difference in the prevalence
of AF between surgery with or without cardiopul-
monary bypass [3, 4]. Controlled studies have re-
vealed that beta-blockers significantly reduce the
occurrence and duration of AF attacks and the ven-
tricular rate during these attacks [5, 6]. The still
expanding potential of ACE inhibitors as hypoten-
sive, anti-atherosclerotic, hemodynamic and, ac-
cording to the results of the EUROPA study, anti-
ischemic drugs, may have anti-arrhythmic implica-
tions [7]. We evaluated different clinical and
biochemical predictors as well as pharmacothera-
py in patients with late (4 or 5 days or more after
surgery) new-onset AF CABG in a retrospective
analysis.
Methods
Retrospective analysis was conducted of the
medical records of 217 consecutive patients,
156 men and 61 women, with no history of AF who
had undergone coronary surgery between January
2000 and December 2002. The patients had been
admitted to the Ischemic Heart Disease Depart-
ment after the 4th postoperative day. Patients who
had undergone classical CABG surgery and OPCA-
BG who were on sinus rhythm on the day of admis-
sion were included in the analysis. The diagnosis
of paroxysmal AF, which took place after admission,
was based on standard 12-lead ECG examination.
Short transient episodes of AF in the first three days
after CABG were not a subject of analysis. The
drugs applied were evaluated retrospectively.
Database management and statistical analysis were
performed using the SAS statistical package (ver-
sion 8e). For descriptive purposes, all data are pre-
sented as mean – SD (continuous variables) or ab-
solute frequencies and percentages where indicat-
ed (discrete variables). The normality of the data
distribution was tested by the Shapiro-Wilk test.
Differences in continuous variables between groups
(AF+ and AF) were analysed using Students
t-test. The c2 test was used for qualitative variables.
All test procedures were two-sided with a p value
of less than 0.05 indicating statistical significance.
Multivariate logistic regression analysis was per-
formed to determine which of these significant uni-
variate predictors of AF provided prognostic infor-
mation not provided by the others. A model was
developed that incorporated only variables of poten-
tial statistical significance (p < 0.05 required to
enter the logistic regression model). The study
complies with the Declaration of Helsinki. All pa-
tient data was confidential. The research protocol
was approved by the Scientific Committee of the
Institute of Cardiology, Warsaw, Poland.
Results
The mean age of the patients was: 62.3 years,
mean body mass index (BMI) was 27.1 and the mean
history of coronary artery disease was 4.9 years
since myocardial infarction or the onset of symp-
toms. The mean duration of hospital stay was
10 days. Paroxysmal AF, confirmed in 12-lead ECG
examination, occurred in 28% (61/217) of patients
with no previous history of this condition (Table 1).
In the univariate analysis the age of patients with
AF was higher: 65.2 – 7.7 (SEM 1.1) vs. 61.2 – 9.4
(SEM 0.8), p < 0.05. They had a longer history of
coronary artery disease: 6.3 – 5.7 (0.8) vs. 4.6 –
– 4.9 (0.4), p = 0.0417. More of the patients with AF
had three-vessel disease: 52% vs. 32% (p < 0.05),
and more had > 3 grafts: 13% vs. 2% (p < 0.005).
Ejection fraction was estimated by echocardiogra-
phy (acoustic quantification method) or by contrast
ventriculogram. Patients with a lower ejection fraction
(< 40%) more frequently presented AF in the postop-
erative course: 51% with AF vs. 23% (p < 0.0001)
(Table 1). Ejection fraction (< 40%) was a significant
risk factor in univariate analysis (OR 3.4, 1.86.4)
(Table 2). Multivariate regression analysis identi-
fied two independent predictors of arrhythmia
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events: no ACE inhibitor treatment before surgery
(p = 0.0005) and age > 60 years (OR 8.54, 2.19
57.45, p < 0.01). Treatment with ACE inhibitors
was associated with a significant reduction in the
risk of AF (OR 0.15, 0.050.42) (Table 2). In the
multivariate models neither > 3-vessel disease nor
ejection fraction < 40% was a determinant of the
incidence of AF after coronary surgery. The area
Table 1. Characteristics of the study group, univariate variables.
No atrial fibrillation after surgery Atrial fibrillation after surgery p
No. of patients 156 (72%) 61 (28%)
Baseline demographics
Age [years] 61.2 – 9.4 65.2 – 7.7 0.0033
Gender (male/female) 110/46 46/15 NS
Weight [kg] 78.4 – 12.0 78.9 – 11.6 NS
Body mass index [kg/cm2] 27.4 – 3.5 27.2 – 3.0 NS
Duration of CAD [years] 4.6 – 4.9 6.3 – 5.7 0.0417
Diabetes mellitus 25 (16%) 8 (13%) NS
Hypertension 115 (74%) 44 (72%) NS
Hyperlipidemia 128 (82%) 48 (79%) NS
Smoking history 67 (43%) 21 (34%) NS
History of myocardial infarction 84 (54%) 39 (64%) NS
NYHA functional class
I 33 (21%) 19 (31%) NS
II 99 (63%) 36 (59%) NS
III 23 (15%) 5 (8%) NS
IV  1 (1%) 1 (2%) NS
CCS functional class: IIIIV 103 (66%) 33 (55%) NS
Ejection fraction < 40% 36 (23%) 31 (51%) < 0.0001
‡ 3 vessel disease 50 (32%) 32 (52%) < 0.01
‡ 3 grafts 3 (2%) 8 (13%) < 0.005
Therapy: before CABG
Beta-blocker 151 (97%) 46 (75%) < 0.0001
ACE-inhibitor 100 (64%) 9 (15%) < 0.0001
Beta-blocker and ACE-inhibitor 98 (63%) 7 (11.5%) < 0.0001
Therapy: after CABG
Beta-blocker 155 (99%) 36 (59%) < 0.0001
ACE-inhibitor 120 (77%) 5 (8%) < 0.0001
Beta-blocker and ACE-inhibitor 119 (76%) 5 (8%) < 0.0001
CAD  coronary artery disease, NYHA  New York Heart Association, CCS  the Canadian Cardiovascular Society, CABG  coronary artery bypass
grafting, ACE  angiotensin converting enzyme
Table 2. Univariate and multivariate logistic analyses of selected variables.
Univariate analysis                               Multivariate analysis
Odds ratio p Adjusted odds ratio p
Age > 60 years 2.31 (1.14.82) < 0.05 8.54 (2.1957.45) < 0.01
ACE-inhibitor before 0.10 (0.040.21) < 0.0001 0.15 (0.050.42) 0.0005
Ejection fraction < 40% 3.4 (1.86.4) < 0.0001 1.57 (0.633.91) NS
‡ 3-vessel disease 2.3 (1.34.3) < 0.05 1.06 (0.511.90) NS
‡ 3 grafts 7.7 (2.030.1) < 0.005 1.11 (0.050.42) NS
ACE  angiotensin converting enzyme
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under a receiver operating characteristic was 0.815
for all significant parameters in multivariate analy-
sis. Patients with AF had a significantly higher mean
heart rate (evaluated by 12-lead ECG examination)
before incurring the arrhythmia: 101 – 36 vs. 77 –
– 15 (p < 0.00001). Patients with an AF episode
had a higher level of leukocytes after surgery
(+3700 – 4300, p < 0.0001). There were no signif-
icant differences in red blood cell counts, hemoglob-
in, hematocrit, platelets or biochemical parameters
(sodium, potassium, creatinine, BUN, glucose) be-
tween groups. Patients treated with beta-blockers
before surgery had a lower incidence of AF: 23% vs.
75% in patients not treated (p < 0.0001). Treatment
with beta-blockers introduced (as a continuation or
start) after CABG resulted in a significantly lower
incidence of AF: 19% vs. 96% in those not treated
(p < 0.0001) (Fig. 1, 2). Patients with AF who were
not treated with beta-blockers had a mean heart rate
of 115 – 34 per minute. In contrast, the mean heart
rate of the patients treated was 78 – 21 (p <
< 0.0005). In multivariate regression analysis treat-
ment with ACE inhibitors before surgery was as-
sociated with a lower risk of AF episodes in spite
of higher BMI, lower ejection fraction and a small-
er number of grafts in patients treated with ACE
inhibitors. Administration of ACE inhibitors was
associated with a lower incidence of AF before and
after surgery: 8% vs. 48% of patients not treated
(p < 0.0001) and 4% vs. 61% (p<0.0001) respec-
tively (Fig. 1, 2). Patients treated with ACE inhib-
itors and beta-blockers before and after CABG had
a consistently lower incidence of AF than those not
treated: 7% vs. 48% (p < 0.0001), and 4% vs. 60%
(p < 0.0001) respectively (Fig. 1, 2). No AT1-
-receptor blockers and amiodarone were used.
Treatment with statins did not have any influence
on AF occurrence or its course. None of the patients
studied left the hospital with persistent AF.
Concurrent analysis of all variables was not
possible because of the multi-colinearity of many
of them. Statistical fitting of the models including
most of the variables was questionable, therefore
many parameters were removed for redundancy.
Twenty variant models were tested.
Discussion
Although AF after cardiac surgery is quite
a common complication, its pathogenesis has not
been sufficiently clarified. Most studies report the
occurrence of AF between the second and third
postoperative days [3]. In our study patients were
analysed who, on average, had been admitted to our
department after the fourth postoperative day, when
the general condition of a patient is considered to
be stable. The mean duration of hospitalisation was
10 days. In a meta-analysis of 17 trials (980 patients)
the peak incidence of AF was on the second and
third day (2237%). Between the fourth to tenth
postoperative days this incidence did not exceed
10% [1]. In our analysis AF occurred in 28.6% of
the patients. We did not analyse brief transient self-
limited episodes of AF in the intraoperative and
early postoperative settings.
One of the most common risk factors confirmed
in the majority of studies is advanced age. Sclerot-
ic changes within the atrial myocardium, endocar-
dium, and epicardium result in fragmentation of dis-
tinct endocardial layers, infiltration of elastic and
collagenous elements, and atrophy of atrial myo-
cytes [8]. In addition to hemodynamic ventricular
Figure 1. The influence of treatment before surgery on
the onset of atrial fibrillation (AF); BB  beta-blockers;
ACEI  angiotensin-converting enzyme inhibitors;
n  number of patients.
Figure 2. The influence of treatment after surgery on
the onset of atrial fibrillation (AF); BB  beta-blockers;
ACEI  angiotensin-converting enzyme inhibitors;
n  number of patients.
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and atrial influences, these changes promote intra-
atrial conduction disturbances, non-uniform anisot-
ropy and increased dispersion of refractoriness.
Goette et al. [9] demonstrated that atrial fibrosis is
an important pathophysiological substrate for post-
operative AF. In a study from Leitch et al. [10],
17.2% of 5807 patients had AF: in the group below
40 years of age the incidence of AF was 3.7%, while
in the group above 70 years it was 27.7%. A longer
history of coronary disease correlates with age and
the degree of changes in the atrial and ventricular
myocardium. The study by Leitch et al. [10] cited
above showed that 18% of patients with AF had dis-
ease of three more vessels and/or left main vessel
disease, in comparison with 15.9% with < 3 vessels
involved and without the left-main. The number of
grafts corresponds to the degree of preoperative
coronary disease and the duration of surgery. In our
study 14% of AF patients had > 3 grafts, in com-
parison with only 2% patients in the non-AF group
(p = 0.0018). This is in agreement with Leitchs
observations, but the results of other smaller stud-
ies do not support these reports [11]. There were
no significant differences in the mean values of bi-
ochemical parameters between groups, but patients
treated with ACE inhibitors had a tendency towards
higher levels of sodium and potassium.
Patients with a higher postoperative heart rate
had a higher risk of AF due to autonomic imbalance.
There is still controversy as to whether this is va-
gal or sympathetic in nature. Amar at al. [12] sug-
gest parasympathetic resurgence competing with
increasing sympathetic activity as a triggering
mechanism for postoperative AF. Patients with AF
had a higher level of white blood cells after surgery
(+3700 – 4300, p < 0.0001). The white blood cell
count is a marker of inflammation. According to
a study by Sajadieh et al. [13], altered autonomic
balance (increased heart rate and reduced heart-rate
variability) can trigger inflammation and inflamma-
tion may, in turn, influence the autonomic balance;
these processes can potentiate each other in healthy
elderly subjects. These effects can be even more
pronounced in patients with coronary artery disease
(i.e. atherosclerosis) and can promote arrhythmia.
Opinions vary on preventive drug treatment and
how it should be administered. Digoxin has been
used but, because of its narrow index of therapeutic
concentrations, this was unsafe [2]. Class I and III
anti-arrhythmic drugs are considered to be as ef-
fective in preventing and terminating episodes of
AF as beta-blockers and calcium antagonists.
The prophylactic use of beta-blockers in the
preoperative and postoperative periods is regarded
as safe and beneficial in reducing the risk of AF
and other forms of supraventricular arrhythmia.
Beta-adrenergic stimulation increases atrial ecto-
py and shortens refractoriness, providing substrates
for AF. It is more common in diseased hearts and
is usually preceded by physical stress and an in-
crease in heart rate [14]. In our study patients with
AF had a significantly higher heart rate. Aside from
pharmacological interventions, catecholamine ex-
cess may be due to emotional stress and hemody-
namic changes. Patients after cardiac surgery who
develop AF have higher norepinephrine levels than
controls without arrhythmia [15]. Beta-blockers are
safe and valuable drugs that suppress automatici-
ty, prolong refractory periods and slow conduction
velocity [2]. There are increasing data to indicate
that beta-blocker withdrawal is more pro-arrhyth-
mic, because of the increased beta-adrenergic re-
ceptor density in patients treated with these drugs,
which makes them more sensitive to catecholamine
stimulation in the absence of beta-blockers [16].
In our study 10% fewer patients with AF were treat-
ed with beta-blockers after surgery (76% vs. 66%).
In the group without AF only 2% had beta-blocker
treatment discontinued (90% vs. 88%).
On the other hand, many postoperative beta-
blocker prevention trials have failed to demonstrate
their protective effect [17]. There are many stud-
ies of preoperative beta-blocker usage with varied
results. No clear relationship has been demonstrat-
ed between preoperative beta-blockers and a reduc-
tion in the incidence of AF. Generally, abrupt ces-
sation of beta-blockers is hazardous because of their
obvious indications, namely coronary artery disease
and its possible complications: worsening angina,
myocardial infarction, risk of sudden death and ar-
rhythmia [18]. The consensus is that non-selective
and selective beta-blockers are well tolerated and
efficacious in reducing the risk of AF after surgery.
This has been demonstrated in many trials and con-
firmed in two meta-analyses by Kovey et al. [5]
(7 trials, 1418 patients, 20.2% vs. 9.8% p < 0.001)
and Andrews et al. [6] (18 trials, 1549 patients, 34%
vs. 8.7%, p < 0.0001). Propranolol was used in most
of these. Other beta-blockers include timolol, aten-
olol, acebutolol, nadolol, and metoprolol. Sotalol was
slightly more effective than other beta-blockers,
probably thanks to its additional class III action [19].
Overall, beta-blockers can reduce arrhythmia after
surgery by 50%. Patients should already be treat-
ed before surgery and therapy should be continued
after it [18]. In the long term an effective dose of
a beta-blocker should keep the heart rate to below
70 per minute, because a higher heart rate is
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a significant risk factor of arrhythmia, as confirmed
in our study. The widely accepted long-acting beta-
blockers, (bisoporolol, betaxolol, metoprolol SR),
seem to be more effective because of their phar-
macokinetic and pharmacodynamic properties, re-
sulting in continuous blockade of beta-1 receptors.
Angiotensin II promotes activation of fibrob-
lasts and collagen accumulation, which leads to
structural remodelling. The development of inter-
stitial changes induced by MAP kinases increases
the likelihood of AF. AF itself perpetuates the de-
velopment of structural atrial alterations by in-
creased expression of ACE and aldosterone [20].
Dipeptidil peptidase IV activity and atrial ACE ex-
pression are significantly increased as well, result-
ing in lower bradikinine levels during AF, which
may contribute to degenerative changes [21]. An-
other mechanism of the deleterious action of angio-
tensin II is an increase in the calcium influx
through L channels by the activation of protein
kinase C and the phosphorylation of the channels [22].
Inhibition of the potassium current may influence
the voltage of the action potential plateau and af-
fect repolarisation [23]. Angiotensin II also inhib-
its junctional conduction, which increases the risk
of re-entrant ventricular arrhythmia [24]. Nakashi-
ma et al. [25] demonstrated in an experimental
study that angiotensin II contributes to atrial elec-
trical remodelling.
Angiotensin II increases norepinephrine re-
lease from atrial sympathetic nerves by activation
of prejunctional AT-1 receptors and can cause
a decrease in beta-adrenergic receptor density [26, 27].
Cross-fire, therefore, occurs between the adrener-
gic and RAA systems. In the present study 100%
patients without either ACE inhibitors or beta-
-blockers before or after surgery, had AF, in com-
parison with 32% with any kind of pre-surgical or
post-surgical treatment (p = 0.039). Experimental
work by Shi at al. [28] proved that ACE inhibition
with enalapril attenuates heart-failure-induced atrial
fibrosis and remodelling and reduces the risk of AF.
Pedersen et al. [29] have shown in a sub-analysis
of the TRACE study that prophylactic ACE inhi-
bitor therapy reduces the risk of AF in patients af-
ter myocardial infarction. In hypertension and heart
failure AF is a consequence of altered signal trans-
duction [9]. In our study 32% of patients had a low
ejection fraction of < 40%, which is an additional
argument for possible ACE inhibitor efficacy
(Table 2). In addition to their beneficial influence
on the electrolyte profile, the potential mechanisms
of the deleterious action of angiotensin II mentioned
above make treatment with ACE inhibitors logical.
Recently many experimental studies on the subject
have been published.
Our results, which were first published as an
abstract in 2003 [30], are consistent with the results
of a multicentre prospective observational study by
Mathew et al. [31]. In this study AF occurred in
32.3% of patients after CABG (1503/4657). A re-
duced risk of AF episodes was associated with the
postoperative administration of beta-blockers
(OR 0.32, 95% CI 0.220.46), ACE inhibitors
(OR 0.62; 95% CI 0.480.79), potassium supplemen-
tation (OR 0.32; 95% CI 0.420.68) and non-steroidal
anti-inflammatory drugs (OR 0.49; 95% CI 0.40
0.60) Withdrawal of beta-blockers and ACE inhib-
itors resulted in a significant increase in the odds
of developing AF. Further clinical prospective stud-
ies are needed to clarify this issue.
Limitations of the study
The study is limited by its method, the retro-
spective analysis of patients files. The analysis
encompassed consecutive patients transferred to
our department following bypass surgery. The other
potential limitations are the differences in the kinds
of ACE inhibitor and beta-blockers used and the
varied doses of these drugs.
Conclusions
ACE inhibitor therapy may be effective in the
prophylaxis of new-onset atrial fibrillation Advanced
age, duration of coronary artery disease, the number
of grafts, reflecting the duration of the procedure, and
a low ejection fraction are strong probable predictors
for post-discharge atrial fibrillation following cardi-
ac surgery. Therapy based on individual variables is
crucial for proper treatment and diminishing the risk
of arrhythmia. We believe that optimal pharmacolog-
ical treatment with beta-blockers and ACE inhibitors
with proper dose and drug selection is an effective
method of preventing arrhythmia.
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